An update on pharmacotherapy of autism spectrum disorder in children and adolescents
The DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Abstract
To date, no medication is proven to be effective in treating core symptoms of autism spectrum disorder (ASD). Psychotropic medications are widely used to target emotional and behavioural symptoms in ASD. This article reviewed evidence for pharmacotherapy, novel therapeutic agents, and Complementary and Alternative Medicine (CAM) in children and adolescents with ASD. Currently, only risperidone and aripiprazole have been approved by the US Food and Drug Administration (FDA) for treatment of irritability associated with ASD in children and adolescents. However, associated metabolic side-effects are concerning. Evidence supports use of methylphenidate and atomoxetine for attention deficit hyperactivity disorder (ADHD) symptoms and clonidine and guanfacine ER appear to be helpful. SSRIs are poorly tolerated and lack evidence in reducing restricted repetitive behaviours (RRB), anxiety, and depression. Buspirone shows promise in the treatment of RRB. The evidence is inconsistent for the effectiveness of anti-epileptic medications. Recent studies of glutamatergic, Gamma-aminobutyric acid (GABA)ergic, and cholinergic agents and oxytocin show inconsistent results. Despite wide use of CAM agents, the evidence is inconclusive. Melatonin can be helpful in reducing sleep problems. Overall, the evidence is limited for pharmacotherapy in children with ASD, and side-effects with long-term use can be burdensome.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Risperidone in Children with Autism and Serious Behavioral Problems
McCracken, J. T., McGough, J., Shah, B., Cronin, P., Hong, D., Aman, M. G., Arnold, L. E., Lindsay, R., Nash, P., Hollway, J., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa013171 · Cited by 1,574 · cited 6×
“…irritability (agitation, anger outbursts, and self-injurious behaviour), stereotypy, and hyperactivity (Ichikawa et al., 2016; Kent et al., 2013; Marcus et al., 2009; McCracken et al., 2002; McDougle et al., 2005; Owen et al., 2009; Pandina, Bossie, Youssef, Zhu, & Dunbar, 2007; Shea et al., 2004).”
BackgroundMethodInfluentialNeuroanatomic observations of the brain in autism: a review and future directions
Bauman, M. L., & Kemper, T. L. (2005) · International Journal of Developmental Neuroscience · doi:10.1016/j.ijdevneu.2004.09.006 · Cited by 919 · cited 1×
“Cholinergic system abnormalities have been hypothesized in individuals with ASD (Bauman & Kemper, 2005; Deutsch, Urbano, Neumann, Burket, & Katz, 2010; Karvat & Kimchi, 2014; Lee et al., 2002; Perry et al., 2001).”
BackgroundConsensus Paper: Pathological Role of the Cerebellum in Autism
Fatemi, S. H., Aldinger, K. A., Ashwood, P., Bauman, M. L., Blaha, C. D., Blatt, G. J., Chauhan, A., Chauhan, V., Dager, S. R., Dickson, P. E., et al. (2012) · The Cerebellum · doi:10.1007/s12311-012-0355-9 · Cited by 723
Aripiprazole in the Treatment of Irritability in Children and Adolescents With Autistic Disorder
Owen, R., Sikich, L., Marcus, R. N., Corey-Lisle, P., Manos, G., McQuade, R. D., Carson, W. H., & Findling, R. L. (2009) · Pediatrics · doi:10.1542/peds.2008-3782 · Cited by 613 · cited 3×
“Multiple large RDBPC trials have shown results supporting that both medications are superior to placebo in alleviating irritability (agitation, anger outbursts, and self-injurious behaviour), stereotypy, and hyperactivity (Ichikawa et al., 2016; Kent et al., 2013; Marcus et al., 2009; McCracken et al., 2002; McDougle…”
BackgroundMethodSelf-citationReichow, B. (2012) · Journal of Autism and Developmental Disorders · doi:10.1007/s10803-011-1218-9 · Cited by 584 · cited 1×
“However, these treatments have limited accessibility, due to their high cost and the intense labour involved (Reichow, 2012; ViruesOrtega, Julio, & Pastor-Barriuso, 2013).”
Background(2005) · Archives of General Psychiatry · doi:10.1001/archpsyc.62.11.1266 · Cited by 521
King, B. H., Hollander, E., Sikich, L., McCracken, J. T., Scahill, L., Bregman, J. D., Donnelly, C. L., Anagnostou, E., Dukes, K., Sullivan, L., et al. (2009) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2009.30 · Cited by 482
Sulforaphane treatment of autism spectrum disorder (ASD)
Singh, K., Connors, S. L., Macklin, E. A., Smith, K. D., Fahey, J. W., Talalay, P., & Zimmerman, A. W. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1416940111 · Cited by 449
Bakermans-Kranenburg, M. J., & van IJzendoorn, M. H. (2013) · Translational Psychiatry · doi:10.1038/tp.2013.34 · Cited by 383
Aman, M. G., Mcdougle, C. J., Scahill, L., Handen, B., Arnold, L. E., Johnson, C., Stigler, K. A., Bearss, K., Butter, E., Swiezy, N. B., et al. (2009) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/chi.0b013e3181bfd669 · Cited by 371
Van IJzendoorn, M. H., & Bakermans-Kranenburg, M. J. (2012) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2011.07.008 · Cited by 365 · cited 1×
“…e fo r fo la te re ce pt or -a au to an tib od y N on e no te w or th y AS D :a ut is m sp ec tr um di so rd er ;R RB :r es tr ic te d an d re pe tit iv e be ha vi ou rs . improving social cognition and RRB (BakermansKranenburg & Van IJzendoorn, 2013; Van IJzendoorn & Bakermans-Kranenburg, 2012).”
BackgroundIntranasal oxytocin treatment for social deficits and biomarkers of response in children with autism
Parker, K. J., Oztan, O., Libove, R. A., Sumiyoshi, R. D., Jackson, L. P., Karhson, D. S., Summers, J. E., Hinman, K. E., Motonaga, K. S., Phillips, J. M., et al. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1705521114 · Cited by 349 · cited 1×
“In contrast, oxytocin improved social functioning as compared to placebo in children with ASD, as measured by SRS in a recent RDBPC (Parker et al., 2017).”
BackgroundYatawara, C. J., Einfeld, S. L., Hickie, I. B., Davenport, T. A., & Guastella, A. J. (2016) · Molecular Psychiatry · doi:10.1038/mp.2015.162 · Cited by 344
Clonidine Treatment of Hyperactive and Impulsive Children with Autistic Disorder
JASELSKIS, C. A., COOK, E. H., FLETCHER, K. E., & LEVENTHAL, B. L. (1992) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-199210000-00005 · Cited by 328
A randomised controlled trial of bumetanide in the treatment of autism in children
Lemonnier, E., Degrez, C., Phelep, M., Tyzio, R., Josse, F., Grandgeorge, M., Hadjikhani, N., & Ben-Ari, Y. (2012) · Translational Psychiatry · doi:10.1038/tp.2012.124 · Cited by 322
Gringras, P., Nir, T., Breddy, J., Frydman-Marom, A., & Findling, R. L. (2017) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1016/j.jaac.2017.09.414 · Cited by 306
Self-citationGuastella, A. J., Gray, K. M., Rinehart, N. J., Alvares, G. A., Tonge, B. J., Hickie, I. B., Keating, C. M., Cacciotti‐Saija, C., & Einfeld, S. L. (2015) · Journal of Child Psychology and Psychiatry · doi:10.1111/jcpp.12305 · Cited by 299
Nasal oxytocin for social deficits in childhood autism: A randomized controlled trial
Dadds, M. R., MacDonald, E., Cauchi, A., Williams, K., Levy, F., & Brennan, J. (2014) · Journal of Autism and Developmental Disorders · doi:10.1007/s10803-013-1899-3 · Cited by 250
Lee, D. O., & Ousley, O. Y. (2006) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2006.16.737 · Cited by 239 · cited 1×
“ADHD is a frequent co-occurring condition in children with ASD, with data showing that 37% (Gadow, DeVincent, & Pomeroy, 2006) to 85% (Lee & Ousley, 2006) of children with ASD have an ADHD diagnosis.”
BackgroundNicotinic receptor abnormalities in the cerebellar cortex in autism
Lee, M. (2002) · Brain · doi:10.1093/brain/awf160 · Cited by 232
Hollander, E., Soorya, L., Chaplin, W., Anagnostou, E., Taylor, B. P., Ferretti, C. J., Wasserman, S., Swanson, E., & Settipani, C. (2012) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2011.10050764 · Cited by 224 · cited 14×
“In contrast, Autism Speaks released findings from an unpublished industry-sponsored large RDBPC study of fluoxetine in children and adolescents with ASD (SOFIA), indicating no improvement in RRB (Autism Speaks Press release, 2009).”
BackgroundInfluentialAn update on pharmacotherapy for autism spectrum disorder in children and adolescents
Ji, N. Y., & Findling, R. L. (2015) · Current Opinion in Psychiatry · doi:10.1097/yco.0000000000000132 · Cited by 217
Self-citationNaltrexone in autistic children: Behavioral symptoms and attentional learning
CAMPBELL, M., ANDERSON, L. T., SMALL, A. M., ADAMS, P., GONZALEZ, N. M., & ERNST, M. (1993) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/00004583-199311000-00024 · Cited by 210 · cited 1×
“In an RDBPC study of children with ASD, naltrexone was superior to placebo in improving hyperactivity (Campbell et al., 1993).”
BackgroundExtended-Release Guanfacine for Hyperactivity in Children With Autism Spectrum Disorder
Scahill, L., McCracken, J. T., King, B. H., Rockhill, C., Shah, B., Politte, L., Sanders, R., Minjarez, M., Cowen, J., Mullett, J., et al. (2015) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2015.15010055 · Cited by 201
Arbaclofen in fragile X syndrome: results of phase 3 trials
Berry-Kravis, E., Hagerman, R., Visootsak, J., Budimirovic, D., Kaufmann, W. E., Cherubini, M., Zarevics, P., Walton-Bowen, K., Wang, P., Bear, M. F., et al. (2017) · Journal of Neurodevelopmental Disorders · doi:10.1186/s11689-016-9181-6 · Cited by 183
Harfterkamp, M., van de Loo-Neus, G., Minderaa, R. B., van der Gaag, R.-J., Escobar, R., Schacht, A., Pamulapati, S., Buitelaar, J. K., & Hoekstra, P. J. (2012) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1016/j.jaac.2012.04.011 · Cited by 171 · cited 1×
“Atomoxetine improved hyperactivity but not global functioning compared to placebo in an RDBPC trial of children with ASD, with further improvement during the open-label extension over 28 weeks (Harfterkamp et al., 2012, 2013).”
MethodA pilot randomized controlled trial of omega-3 fatty acids for autism spectrum disorder
Bent, S., Bertoglio, K., Ashwood, P., Bostrom, A., & Hendren, R. L. (2011) · Journal of Autism and Developmental Disorders · doi:10.1007/s10803-010-1078-8 · Cited by 156
Handen, B. L., Aman, M. G., Arnold, L. E., Hyman, S. L., Tumuluru, R. V., Lecavalier, L., Corbett-Dick, P., Pan, X., Hollway, J. A., Buchan-Page, K. A., et al. (2015) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1016/j.jaac.2015.08.013 · Cited by 147
Pandina, G. J., Bossie, C. A., Youssef, E., Zhu, Y., & Dunbar, F. (2007) · Journal of Autism and Developmental Disorders · doi:10.1007/s10803-006-0234-7 · Cited by 144
Jahromi, L. B., Kasari, C. L., McCracken, J. T., Lee, L. S.-Y., Aman, M. G., McDougle, C. J., Scahill, L., Tierney, E., Eugene Arnold, L., Vitiello, B., et al. (2009) · Journal of Autism and Developmental Disorders · doi:10.1007/s10803-008-0636-9 · Cited by 144
Ghanizadeh, A., Sahraeizadeh, A., & Berk, M. (2014) · Child Psychiatry & Human Development · doi:10.1007/s10578-013-0390-x · Cited by 134
Ooi, Y., Weng, S.-J., Kossowsky, J., Gerger, H., & Sung, M. (2016) · Pharmacopsychiatry · doi:10.1055/s-0042-109400 · Cited by 131
Kosaka, H., Okamoto, Y., Munesue, T., Yamasue, H., Inohara, K., Fujioka, T., Anme, T., Orisaka, M., Ishitobi, M., Jung, M., et al. (2016) · Translational Psychiatry · doi:10.1038/tp.2016.152 · Cited by 117
Deutsch, S. I., Urbano, M. R., Neumann, S. A., Burket, J. A., & Katz, E. (2010) · Clinical Neuropharmacology · doi:10.1097/wnf.0b013e3181d6f7ad · Cited by 99
Roy, A., Roy, M., Deb, S., Unwin, G., & Roy, A. (2015) · Journal of Intellectual Disability Research · doi:10.1111/jir.12122 · Cited by 82
Cited by
Cannabinoid treatment for autism: a proof-of-concept randomized trial
Aran, A., Harel, M., Cassuto, H., Polyansky, L., Schnapp, A., Wattad, N., Shmueli, D., Golan, D., & Castellanos, F. X. (2021) · Molecular Autism · doi:10.1186/s13229-021-00420-2 · Cited by 223
“Food and Drug Administration (FDA) to treat comorbid irritability [2] but these medications often cause obesity and metabolic syndrome [2, 39].”
BackgroundIntranasal oxytocin in the treatment of autism spectrum disorders: A multilevel meta-analysis
Huang, Y., Huang, X., Ebstein, R. P., & Yu, R. (2021) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2020.12.028 · Cited by 119
Ventura, P., de Giambattista, C., Trerotoli, P., Cavone, M., Di Gioia, A., & Margari, L. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11102922 · Cited by 22
Metadata
- Authors
- Goel, R., Hong, J. S., Findling, R. L., & Ji, N. Y.
- Venue
- International Review of Psychiatry
- Publisher
- Informa UK Limited
- Published
- 2018-01-02
- Volume
- 30
- Issue
- 1
- Pages
- 78-95
- ISSN
- 0954-0261 (ISSN-L)
- 1369-1627
- OpenAlex
- W2802198909
- Cited by
- 176
- References
- 35
- FWCI
- 12.03
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.